Immuno-Oncology | Specialty

Future Focus on Combinations, Biomarkers in Metastatic NSCLC

August 1st 2017

The therapeutic paradigm continues to evolve in advanced non-small cell lung cancer, with increased emphasis being placed on rational combinations and biomarkers in the next few years.

New Strategy Boosts Microenvironment to Promote Antitumor Immunity in GI Metastases

August 1st 2017

Despite the promise of immunotherapy for treating patients with advanced cancers, the success of using such therapies for progressive gastrointestinal malignancies such as colorectal liver metastases (CRLM) has been limited so far.

Prostate Cancer: Advice for Oncologists on AR-V7 Testing

July 31st 2017

Experimental Strategies for AR-V7+ CRPC

July 31st 2017

Precision Medicine in mCRPC

July 31st 2017

Recent AR-V7 Data in Prostate Cancer

July 31st 2017

Prostate Cancer: Educating Physicians About AR-V7 Testing

July 31st 2017

Practical Implications of AR-V7 Testing in Prostate

July 31st 2017

Prostate Cancer: Validation of AR-V7 Testing

July 31st 2017

John's Hopkins AR-V7 Test in Prostate

July 31st 2017

Prostate Cancer: Epic Sciences AR-V7 Test

July 31st 2017

Detection of AR-V7 in Prostate Cancer

July 31st 2017

AR-V7 as a Predictive Marker in Prostate Cancer

July 31st 2017

Prostate Cancer: Discovery and Importance of AR-V7

July 31st 2017

The Biology of Prostate Cancer

July 31st 2017

FDA Grants Durvalumab Breakthrough Designation for NSCLC

July 31st 2017

The FDA has granted durvalumab a breakthrough therapy designation to treat patients with locally-advanced, unresectable non-small cell lung cancer whose disease has not progressed following platinum-based chemoradiation.

Dr. Stein Discusses Skin-Related AEs With Melanoma Treatment

July 28th 2017

Jennifer A. Stein, MD, PhD, an associate professor of dermatology at New York University School of Medicine in New York, discusses the skin-related adverse events (AEs) associated with melanoma treatment.

Therapeutic Options Developing for Non-Driver NSCLC, But Challenges Remain

July 27th 2017

Corey Langer, MD, discusses KEYNOTE-189, the current arena in NSCLC treatment, and the obstacles that remain in effectively treating patients with non-driver mutations.

Frontline Durvalumab Plus Tremelimumab Falls Short in Phase III NSCLC Trial

July 27th 2017

Frontline durvalumab (Imfinzi) did not improve progression-free survival in patients with stage IV metastatic non–small cell lung cancer compared with standard platinum-based chemotherapy.

Dr. Pavlick on Adjuvant Immunotherapy in High-risk Melanoma

July 27th 2017

Anna C. Pavlick, DO, associate professor of hematology and medical oncology and medical director of the Clinical Trials Office at the Perlmutter Cancer Center at NYU Langone Medical Center, discusses the need for adjuvant immunotherapy in patients with high-risk melanoma.